{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T03:49:00Z","timestamp":1648957740815},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00108-021-01028-7","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T08:04:02Z","timestamp":1618905842000},"page":"577-580","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Finerenon bei Patienten mit chronischer Nierenerkrankung und Diabetes mellitus Typ\u00a02"],"prefix":"10.1007","volume":"62","author":[{"given":"C.","family":"Wanner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nitschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"1028_CR1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner\u00a0BM, Cooper\u00a0ME, de Zeeuw\u00a0D, Keane\u00a0WF, Mitch\u00a0WE, Parving\u00a0HH, Remuzzi\u00a0G, Snapinn\u00a0SM, Zhang\u00a0Z, Shahinfar\u00a0S, RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"key":"1028_CR2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic\u00a0V, Jardine\u00a0MJ, Neal\u00a0B, Bompoint\u00a0S, Heerspink\u00a0HJL, Charytan\u00a0DM, Edwards\u00a0R, Agarwal\u00a0R, Bakris\u00a0G, Bull\u00a0S, Cannon\u00a0CP, Capuano\u00a0G et\u00a0al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N\u00a0Engl J Med 380:2295\u20132306","journal-title":"N Engl J Med"},{"key":"1028_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink\u00a0HJL, Stef\u00e1nsson\u00a0BV, Correa-Rotter\u00a0R, Chertow\u00a0GM, Greene\u00a0T, Hou\u00a0F\u2011F, Mann\u00a0JFE, McMurray\u00a0JJV, Lindberg\u00a0M, Rossing\u00a0P, Sj\u00f6str\u00f6m\u00a0CD, Toto\u00a0RD et al (2020) Dapagliflozin in patients with chronic kidney disease. N\u00a0Engl J Med 383:1436\u20131446","journal-title":"N Engl J Med"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01028-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01028-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01028-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T14:05:35Z","timestamp":1619532335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01028-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":3,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["1028"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01028-7","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"24 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Wanner: Beratungst\u00e4tigkeiten und Honorare f\u00fcr Vortr\u00e4ge: AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, MSD. Anderweitig keine. S.\u00a0Nitschmann gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}